Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

210 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA.
Radue EW, Sprenger T, Gaetano L, Mueller-Lenke N, Cavalier S, Thangavelu K, Panzara MA, Donaldson JE, Woodward FM, Wuerfel J, Wolinsky JS, Kappos L. Radue EW, et al. Neurol Neuroimmunol Neuroinflamm. 2017 Aug 9;4(5):e390. doi: 10.1212/NXI.0000000000000390. eCollection 2017 Sep. Neurol Neuroimmunol Neuroinflamm. 2017. PMID: 28828394 Free PMC article.
A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS.
Clanet M, Radue EW, Kappos L, Hartung HP, Hohlfeld R, Sandberg-Wollheim M, Kooijmans-Coutinho MF, Tsao EC, Sandrock AW; European IFNbeta-1a (Avonex) Dose-Comparison Study Investigators. Clanet M, et al. Among authors: radue ew. Neurology. 2002 Nov 26;59(10):1507-17. doi: 10.1212/01.wnl.0000032256.35561.d6. Neurology. 2002. PMID: 12451189 Clinical Trial.
Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a.
Hardmeier M, Wagenpfeil S, Freitag P, Fisher E, Rudick RA, Kooijmans M, Clanet M, Radue EW, Kappos L; European IFN-1a in Relapsing MS Dose Comparison Trial Study Group. Hardmeier M, et al. Among authors: radue ew. Neurology. 2005 Jan 25;64(2):236-40. doi: 10.1212/01.WNL.0000149516.30155.B8. Neurology. 2005. PMID: 15668419 Clinical Trial.
Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
Kappos L, Clanet M, Sandberg-Wollheim M, Radue EW, Hartung HP, Hohlfeld R, Xu J, Bennett D, Sandrock A, Goelz S; European Interferon Beta-1a IM Dose-Comparison Study Investigators. Kappos L, et al. Among authors: radue ew. Neurology. 2005 Jul 12;65(1):40-7. doi: 10.1212/01.wnl.0000171747.59767.5c. Neurology. 2005. PMID: 16009883 Clinical Trial.
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators. Rudick RA, et al. Among authors: radue ew. N Engl J Med. 2006 Mar 2;354(9):911-23. doi: 10.1056/NEJMoa044396. N Engl J Med. 2006. PMID: 16510745 Free article. Clinical Trial.
Health-related quality of life in multiple sclerosis: effects of natalizumab.
Rudick RA, Miller D, Hass S, Hutchinson M, Calabresi PA, Confavreux C, Galetta SL, Giovannoni G, Havrdova E, Kappos L, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators. Rudick RA, et al. Among authors: radue ew. Ann Neurol. 2007 Oct;62(4):335-46. doi: 10.1002/ana.21163. Ann Neurol. 2007. PMID: 17696126 Clinical Trial.
210 results